EID Parry’s nutraceuticals turn profitable, Rs 7.6 crore H1 PBIT

EID Parry’s nutraceuticals business reported PBIT of Rs 7.6 crore in H1 FY27, reversing a Rs 5.3 crore loss in H1 FY26, as revenue rose 1.5 times to Rs 131.2 crore. Parry’s attributed the revenue-led turnaround primarily to volume growth from its Hair & Derm portfolio, while Serevelle drove revenue and profitability.

How did Parry’s nutraceuticals return to profit in H1 FY27?

Parry’s moved from a PBIT loss of Rs 5.3 crore in H1 FY26 to PBIT of Rs 7.6 crore in H1 FY27, an improvement of Rs 12.9 crore across the two half-year periods. The presentation describes the outcome as profitability from revenue-led growth and does not identify a separate cost-reduction figure for the nutraceuticals business.

The H1 FY26 comparator excludes a one-time insurance claim receipt of Rs 18 crore. This means the stated movement to Rs 7.6 crore of H1 FY27 PBIT is measured against an adjusted H1 FY26 PBIT loss rather than a prior-period result including that insurance receipt.

Parry’s reported total nutraceuticals revenue of Rs 131.2 crore in H1 FY27, compared with Rs 88.2 crore in H1 FY26. The Rs 43 crore increase is consistent with management’s statement of 1.5-times revenue growth, with volumes primarily from the Hair & Derm portfolio identified as the main driver.

The presentation does not disclose nutraceuticals operating margin, unit volumes, selling prices or quarterly PBIT for Q2 FY27. It therefore shows a half-year PBIT turnaround in H1 FY27, but does not quantify how much of the Rs 7.6 crore result came from individual products, price movements or each revenue category.

Which categories produced Parry’s H1 FY27 revenue growth?

Parry’s largest reported revenue increase came from Prostate Health + Others, which rose by Rs 24.3 crore to Rs 80.4 crore in H1 FY27 from Rs 56.1 crore in H1 FY26. Joint Health recorded the fastest percentage growth among the disclosed categories, increasing by Rs 17.2 crore to Rs 32 crore from Rs 14.8 crore.

Greens rose by Rs 1.4 crore to Rs 18.8 crore in H1 FY27 from Rs 17.4 crore a year earlier. In comparison, the Rs 41.5 crore combined increase in Joint Health and Prostate Health + Others accounted for nearly all of the Rs 43 crore growth in total disclosed category revenue.

Parry’s says Hair & Derm volumes primarily drove the 1.5-times revenue increase and separately identifies Serevelle as a revenue and profitability driver. However, Hair & Derm is not a standalone row in the H1 FY27 category table, so the presentation does not quantify its sales within Prostate Health + Others or another disclosed category.

What products are behind Parry’s H1 FY27 nutraceuticals growth?

Parry’s identifies Serevelle, a Derma and Hair Health product, as having gained significant customer acceptance in H1 FY27 and as driving business revenue and profitability. Management says other product pillars also showed positive traction, contributing to the multi-fold increase in profits reported for the half year.

Serevelle has a granted patent for a composition intended to maintain and promote hair growth and health, with oral-dosage and topical applications stated in the presentation. Parry’s says the product is dominantly sourced from India and refers to trade tariffs normalising as they settle, but does not disclose Serevelle revenue, volume or the tariff cost effect.

The second key product named in Parry’s FY27 strategy is USPlus Pro, positioned in Prostate Health. Its composition has received a patent for maintaining and promoting urinary and prostate function, but the presentation does not state whether it generated H1 FY27 revenue or how it contributed to the Rs 80.4 crore in Prostate Health + Others.

The product disclosures connect commercial priorities with categories of differing revenue scale, including Joint Health at Rs 32 crore and Prostate Health + Others at Rs 80.4 crore in H1 FY27. The source provides no standalone Derm, Hair Health or USPlus Pro revenue category, limiting assessment of each product’s contribution to the Rs 131.2 crore total.

What is Parry’s nutraceuticals plan for FY27?

Parry’s FY27 plan focuses on capacity utilisation, stronger account management and two key product launches, USPlus Pro and Serevelle. The company also lists efficient running of Nutraceuticals India operations as a strategic focus alongside the H1 FY27 revenue and PBIT improvement.

The plan links commercial execution to USPlus Pro in Prostate Health and Serevelle in Derma and Hair Health. Management’s H1 FY27 update says Serevelle’s customer acceptance is helping revenue and profitability, while describing the remaining product pillars as showing positive traction without providing product-level sales targets.

Parry’s does not disclose an FY27 nutraceuticals revenue target, PBIT target, capacity-addition plan or launch timetable for the two products. It also provides no numerical target for account management or capacity utilisation, making later H2 FY27 revenue and PBIT disclosures the measurable indicators of progress under the FY27 plan.

The business entered H2 FY27 after revenue increased from Rs 88.2 crore to Rs 131.2 crore and PBIT changed from a Rs 5.3 crore loss to a Rs 7.6 crore profit. Based on management’s stated priorities, continued progress depends on capacity utilisation, account management, Nutraceuticals India operations and execution around the two named products.

Conclusion

Parry’s H1 FY27 disclosure shows a revenue-led PBIT turnaround: revenue rose by Rs 43 crore year on year and PBIT improved by Rs 12.9 crore against the presentation’s adjusted H1 FY26 comparison. Prostate Health + Others delivered the largest absolute revenue gain, Joint Health expanded sharply, and management identified Hair & Derm volumes and Serevelle acceptance as contributors.

The next items to watch are execution of Parry’s FY27 priorities on capacity utilisation, account management, Nutraceuticals India operations, USPlus Pro and Serevelle. Subsequent disclosures could show whether H1 FY27 PBIT of Rs 7.6 crore is sustained and provide further detail on product-level sales or the effect of normalising trade tariffs.